COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Date results information initially provided
Type of registration
Prospectively registered

Titles & IDs
Public title
Randomised controlled trial of donor site dressings in paediatric split skin grafts
Scientific title
Randomised controlled trial comparing three different donor site dressings (Sorbact, Cuticerin, Algisite) in paediatric patients undergoing split skin grafting for burn injury in terms of time to re-epithelialisation, pain and itch while dressing on, ease of application, care, and removal, cosmetic appearance of donor site and cost
Secondary ID [1] 284350 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Paediatric Burns 291503 0
Condition category
Condition code
Surgery 291874 291874 0 0
Surgical techniques
Injuries and Accidents 291912 291912 0 0

Study type
Description of intervention(s) / exposure
Three different donor site dressings
- Cuticerin. A smooth acetate gauze dressing impregnated with a water repellant petrolatum ointment
- Sorbact. A hydrogel applied to a mesh dressing designed to absorb bacteria onto itself from the wound bed by hydrophobic reaction
- Algisite. This is a calcium alginate dressing, the most common dressing used on donor sites in this region

All dressings come in premade peel packs, and can be simply applied in theatre directly to the wound bed. This will then be covered with an absorbent second layer dressing (allevyn) and tape (hypafix). Dressings will be removed at seven days to assess the wound, then reapplied if necessary every seven days until full re-epithelialisation
Intervention code [1] 289075 0
Treatment: Other
Comparator / control treatment
Active control - with all dressings being compared against each other. All three dressings currently in use in the department.
Control group

Primary outcome [1] 291792 0
Time to re-epithelialisation assessed in two ways.
- Clinical judgement by surgeon treating the patient
- Blinded second assessment from digital photographs
Timepoint [1] 291792 0
Expected 7-14 days
Primary outcome [2] 291793 0
Pain while dressing in situ. Pain at dressing change. Assessed via multiple methods - FACES-R/NRS/FLACC - depending on age of patient.
Timepoint [2] 291793 0
Expected 7-14 days. Once daily while dressing is on (parent, self report). During clinic visit weekly for nurse report
Primary outcome [3] 291794 0
Cosmetic appearance of donor site by POSAS (Pt and Observor Scar Assessment Scale)
3D camera (for depth/height, and colour)
Ultrasound (for thickness of scar tissue)
Timepoint [3] 291794 0
3 and 6 months
Secondary outcome [1] 307558 0
Dressing costs. Assessment will include
- Nursing time for dressing changes
- Cost of dressings
- Medication costs associated with dressings (analgesia)
all as per current clinical standards
Timepoint [1] 307558 0
Time for dressing change will be measured at each dressing change.
Medication and dressing costs will be totalled once donor site wound has re-epithelialised
Secondary outcome [2] 307559 0
Ease of dressing application. Measures used will include
- flexibility and conformity using a NRS 0-4
- Patient/parent perception – comfort, ease of movement and ease of dressing removal using NRS
- nursing assessment ease of application, care, and removal
Timepoint [2] 307559 0
Until re-epithelialisation. Expected 7-14 days as above. May extend to 28 days in rare cases
Secondary outcome [3] 307690 0
Number of dressing changes
Timepoint [3] 307690 0
Expected dressing change each week at clinical review. If additional dressings are needed (due to strikethrough from wound, or longer time to re-epithelialise) these will be assessed. Expected longest time to remain under dressings is 4 weeks.
Secondary outcome [4] 308595 0
Timepoint [4] 308595 0
Itch with dressings in situ, and at three and six month checks. Itch will be assessed using the Itch man scale < 6years of age by parent report, >6years by self report
This will be assessed four hours after operation (to allow assessment prior to discharge), also at 24 hours by phone call, and at each dressing change as for pain scores.

Key inclusion criteria
Patients of the Stuart Pegg Paediatric Burns Centre (SPPBC) undergoing split skin grafting for burns
Minimum age
0 Years
Maximum age
14 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
Aged >15 years of age
Non-English speaking
Cognitive impairment
Current involvement with Department Communities (Child Safety)

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Sequentially numbered, sealed, opaque envelopes
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computerised sequence generation
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Other design features
Not Applicable
Type of endpoint(s)
Statistical methods / analysis
Primary outcomes of pain and re-epithelialisation with a 5% significance level and a power of 80%, 28 patients per group required. Allowing for 10% drop-out gives 93 patients in total.
Data analysis via SPSS (ver20). ANOVA to assess differences between groups. Non parametric tests where appropriate. Generalised linear mixed model will be utilised to analyse differences in pain and itch over time. Intention to treat analysis with significance of 0.05. Statistician will be contracted to be involved in data analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 2269 0
Royal Children's Hospital - Herston
Recruitment hospital [2] 13925 0
Lady Cilento Children's Hospital - South Brisbane
Recruitment postcode(s) [1] 7938 0
4029 - Royal Brisbane Hospital
Recruitment postcode(s) [2] 26695 0
4101 - South Brisbane

Funding & Sponsors
Funding source category [1] 288992 0
Commercial sector/Industry
Name [1] 288992 0
Abigo Ab
Address [1] 288992 0
Ekonomivagen 5 - 436 33 ASKIM - Sweden
Country [1] 288992 0
Primary sponsor type
Stuart Pegg Paediatric Burns Centre
Royal Children's Hospital
Herston Road
Qld 4029
Secondary sponsor category [1] 287671 0
Name [1] 287671 0
Address [1] 287671 0
Country [1] 287671 0
Other collaborator category [1] 277902 0
Name [1] 277902 0
Queensland Children's Medical Research Institute,
University of Queensland
Address [1] 277902 0
Level Four Foundation Building
Royal Children's Hospital
Herston Road
Qld 4029
Country [1] 277902 0

Ethics approval
Ethics application status
Ethics committee name [1] 290800 0
Royal Children's Hospital HREC
Ethics committee address [1] 290800 0
Level 3 Foundation Building
Royal Children's Hospital
Herston Road
Qld 4029
Ethics committee country [1] 290800 0
Date submitted for ethics approval [1] 290800 0
Approval date [1] 290800 0
Ethics approval number [1] 290800 0

Brief summary
Paediatric split skin grafts leave a donor site, requiring a dressing. The optimum dressing for this site is the subject
of much discussion and debate amongst burns clinicians. In our unit there are currently three dressings in regular
use. We therefore have equipoise to undertake a randomised controlled trial in an effort to determine which is the
best of the three. Outcome measures we will be examining relate to both patients and staff. These outcomes
and itch while the dressing is on
of application, care, and removal
to reepithelialisation
appearance of the donor site
There are a number of such trials in the literature. None of them have directly compared our three dressings
(algisite, cuticerin, sorbact). Few of the trials in the literature have looked at children, so the answer is not already in
the literature.
By using real world controls we hope to find the optimum dressing in our environment. This will become our new
preferred dressing, and will naturally then become the new control against which we will measure the performance
of newer products that will inevitably come onto the market in subsequent years.
Patients will be randomised to one or more of the three arms of the study, without them or the assessing staff being
aware of the contact dressing. We will then measure outcomes with the above aims in mind; using previously
validated scoring systems examining the responses of parents, patients and staff members. We will use both
qualitative and quantitative assessment methods.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 47306 0
Dr Craig McBride
Address 47306 0
Royal Children's Hospital
Herston Road
Herston 4029
Country 47306 0
Phone 47306 0
+61 7 3636 8111
Fax 47306 0
Email 47306 0
Contact person for public queries
Name 47307 0
Dr Craig McBride
Address 47307 0
Royal Children's Hospital
Herston Road
Herston 4029
Country 47307 0
Phone 47307 0
+61 7 3636 8111
Fax 47307 0
Email 47307 0
Contact person for scientific queries
Name 47308 0
Dr Craig McBride
Address 47308 0
Royal Children's Hospital
Herston Road
Herston 4029
Country 47308 0
Phone 47308 0
+61 7 3636 8111
Fax 47308 0
Email 47308 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
What data in particular will be shared?
De-identified data will be made available upon reasonable request to the study authors, and following perusal and approval of such a request by the Children's Health Queensland Human Research Ethics Committee
When will data be available (start and end dates)?
25 years from conclusion of study, in accordance with NHMRC guidelines
Available to whom?
Investigators on reasonable request
Available for what types of analyses?
Re-analysis of original data
How or where can data be obtained?
Data will be emailed to investigators following ethical review and signoff.
What supporting documents are/will be available?
Study protocol
Summary results
Have study results been published in a peer-reviewed journal?
Journal publication details
Publication date and citation/details [1] 2233 0
McBride CA, Kimble RM, Stockton KA. Prospective randomised controlled trial of Algisite™ M, Cuticerin™, and Sorbact® as donor site dressings in paediatric split-thickness skin grafts. Burns Trauma 2018;6:1028. doi:10.1186/s41038-018-0135-y.
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary
This trial was designed to determine which donor site wound dressing was preferred in children. All three dressings in this trial - Sorbact, Algisite M, Cuticerin - were in use in the Pegg Leditschke Children's Burns Centre prior to the trial starting.

101 children were prospectively enrolled in the trial, and characteristics of healing and scarring were assessed with respect to each dressing.

There were no significant differences identified across the three dressings; pain, time to re-epithelialisation, itch, scarring, or cost. Younger patients healed more rapidly than older patients. Thinner skin grafts resulted in better scars at three and six months.

These data are limited to children, and do not show one dressing to be superior to another. As this is was designed as a superiority trial, we do not have the data to be able to state that each dressing is equivalent.